论文部分内容阅读
目的:观察益气活血消积方剂联合介入治疗中晚期原发性肝癌临床疗效。方法:60例中晚期原发性肝癌,分为2组,各30例。对照组采用介入治疗;研究组在对照组治疗基础上联合益气活血消积方。观察3月。结果:总有效率研究组83.33%,对照组63.33%,2组比较,差异有统计学意义(P<0.01)。2组治疗后,基质金属蛋白酶-9(MMP-9)、甲胎球蛋白(AFP)、谷丙转氨酶(ALT)、谷草转氨酶(AST)比较,差异均有统计学意义(P<0.01)。肝功能损害率研究组6.67%,对照组16.67%,2组比较,差异有统计学意义(P<0.05);不良反应总发生率研究组16.67%,对照组33.33%,2组比较,差异有统计学意义(P<0.01)。结论:益气活血消积方剂联合介入治疗中晚期原发性肝癌临床疗效佳,可有效改善患者肝功能损害,降低不良反应发生率,促进病情的预后及转归。
Objective: To observe the clinical efficacy of Yiqi Huoxue Digestion Prescription in combination with interventional treatment of advanced primary liver cancer. Methods: 60 cases of primary liver cancer, divided into two groups, each 30 cases. The control group was treated by interventional therapy. The study group was treated with the combination of Yiqi Huoxue Xiaoji prescription on the basis of the control group. Observe March. Results: The total effective rate was 83.33% in the study group and 63.33% in the control group. There was significant difference between the two groups (P <0.01). After treatment, the differences of MMP-9, AFP, ALT and AST among the two groups were statistically significant (P <0.01). The incidence of liver damage was 6.67% in the study group and 16.67% in the control group, with significant difference between the two groups (P <0.05). The incidence of adverse reactions was 16.67% in the study group and 33.33% in the control group. There was significant difference between the two groups Statistical significance (P <0.01). Conclusion: Yiqi Huoxue Xiaoji prescription combined with interventional treatment of advanced primary liver cancer has good clinical curative effect, which can effectively improve the patients’ liver function damage, reduce the incidence of adverse reactions, and promote the prognosis and prognosis of the disease.